within Pharmacolibrary.Drugs.ATC.V;

model V03AB27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.16666666666666666,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>4-dimethylaminophenol (DMAP) is an aromatic amine used as an antidote to cyanide poisoning, primarily by inducing methemoglobinemia, which binds cyanide ions to form the non-toxic cyanomethemoglobin. It is not generally approved for clinical use in most countries today and is mainly used in emergency or experimental settings, particularly in some European countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters have not been reported in peer-reviewed clinical or preclinical studies in humans. All values below are estimates based on related properties of aromatic amines and known clinical usage.</p><h4>References</h4><ol><li><p>Klimmek, R, et al., &amp; Weger, N (1983). Effects and biotransformation of 4-dimethylaminophenol in man and dog. <i>Archives of toxicology</i> 53(4) 275â€“288. DOI:<a href=&quot;https://doi.org/10.1007/BF00294993&quot;>10.1007/BF00294993</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6639349/&quot;>https://pubmed.ncbi.nlm.nih.gov/6639349</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AB27;
